You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》康方生物-B(09926.HK)超购638倍成「冻资王」 一手中签率12%
阿思达克 04-23 09:35
康方生物-B(09926.HK)公布招股结果,发售价定於16.18元,为上限定价(招股价介乎14.88-16.18元)。公开发售录超购638.2倍,冻结资金逾1,666亿元,成为今年新股「冻资王」,在重新分配後,公开发售股数增至占整体50%,申请一手1,000股中签率仅12%。该股将於明日(24日)挂牌,联席保荐人为摩根士丹利及摩根大通。

国际配售部分亦获非常大幅超额认购。基石投资者已合共认购7,867.2万股,占紧随全球发售完成後公司已发行股本约10.31%。基石投资者共9名,当中Fidelity Investments及Lake Bleu Prime Healthcare Master Funds Limited认购份额较大,分别购入3,137.3万股及2,172万股。

公司预计,所得集资净额为24.37亿元,当中75%将用作产品研发及商业化;15%将用於在中国广州及中山发展生产及研发设施;10%将用於一般公司及营运资金用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account